Empagliflozin, an SGLT2 inhibitor, did not significantly reduce first heart failure hospitalization or death in high-risk patients after a heart attack in the EMPACT-MI trial. However, a secondary analysis showed a significant reduction in first HF hospitalization and total HF hospitalizations with empagliflozin compared to placebo. The drug was deemed safe, but there was no significant difference in overall mortality. The study lacked diversity in enrollment, with primarily male, older, and diabetic patients. Overall, while the primary endpoint was not met, the secondary analysis suggests potential benefits of empagliflozin in preventing HF following a heart attack. Further research is needed to understand the mechanism behind these results.
Source link
Empagliflozin Fails to Reduce Events After Acute MI
